I-Corps: Early Preeclampsia Detection Strip (EPED)

这个i-Corps项目的更广泛的影响/商业潜力是通过改变访问医疗保健的方式来改变医疗保健的进程。早期子痫前期检测(EPED)试纸提供怀孕早期先兆子痫(PE)的非侵入性、快速、定点诊断。及早进行PE检测可以使怀孕更安全。EPED可以帮助临床医生轻松地识别PE，即使在没有出现症状的情况下，也不需要识别白大衣综合征。孕妇可以控制自己的健康，并在家中快速舒适地进行测试。等待检查结果是有压力的，对许多女性来说，去诊所预约是一个巨大的负担。EPED为更好、更快和更多地获得医疗保健提供了答案。提高个人对发生并发症的认识，并为妇女提供控制自己健康所需的工具，对于减轻子痫前期和子痫的负担，并将成千上万的母亲和婴儿从可预防的伤害中拯救出来至关重要。这个i-Corps项目旨在探索先兆子痫诊断的必要性及其设计规范。这一信息的发现将使基于尿液的护理点检测测试的开发成为可能，该测试使用侧向流动技术来测量蛋白质生物标记物的升高水平，这是先兆子痫的指示。该团队已经确定了两个感兴趣的生物标志物，它们与先兆子痫和子痫有关，这在文献和我们的临床工作中得到了证明。当发现高于阈值浓度时，这些生物标志物将确认先兆子痫的发生。为了检测这些生物标志物，该团队选择使用横向流动分析格式，因为它易于使用和高效设计。这一奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project is to change the course of healthcare by changing how it is accessed. The Early Preeclampsia Detection (EPED) Strip provides non-invasive, rapid, point-of-care diagnosis of preeclampsia (PE), early in pregnancy. Early PE detection allows for a safer pregnancy. EPED can aid clinicians to identify PE with ease, even when there are no presenting symptoms, and without the challenge of discerning white coat syndrome. Expecting mothers can take control of their health and test quickly and comfortably at home. Awaiting test results is stressful, and for many women, getting to a clinical appointment poses a huge burden. EPED provides answers for better, faster, and increased access to healthcare. Increasing individual awareness about developing complications and providing women with the tools they need to take control of their own health is essential to reducing the burden of preeclampsia and eclampsia, and saving thousands of mothers and babies from preventable harm.This I-Corps project aims to explore the need for a preeclampsia diagnostic as well as its design specifications. Discovery of this information will allow for the development of a urine-based, point-of-care detection test that uses lateral flow technology to measure elevated levels of protein biomarkers, which are indicative of preeclampsia. The team has identified two biomarkers of interest which are associated with preeclampsia and eclampsia, as evidenced in literature and in our clinical work. When found above threshold concentration, the biomarkers will confirm the development of preeclampsia. To detect these biomarkers, the team has chosen to use a lateral flow assay format because of its ease of use and efficient design.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.